Proposed 30% cancer drug margin cap may hit hospital earnings
In short
A proposed 30% cap on cancer drug margins could hurt hospital earnings, CNBC TV18 Market reported. Macquarie Capital analyst Kunal Dhamesha estimated a mid-teens EBITDA hit for Max Healthcare and a high single-digit impact for Apollo Hospitals.
This could reduce profits for the two hospitals if the cap is imposed. The broader rule and its final scope are not stated in the available reporting.
What the reporting says
A proposed 30% cancer drug margin cap could hurt earnings at Max Healthcare and Apollo Hospitals, according to a CNBC TV18 Market summary citing Macquarie Capital analyst Kunal Dhamesha. He estimated a mid-teens EBITDA hit for Max Healthcare and a high single-digit impact for Apollo Hospitals. The immediate consequence is potential pressure on hospital profitability, while the wider regulatory risk remains not stated in the available reporting.
Why it matters
A CNBC TV18 Market summary said a proposed 30% cancer drug margin cap could weigh on Max Healthcare and Apollo Hospitals. The report quoted Macquarie Capital analyst Kunal Dhamesha, who estimated a mid-teens EBITDA hit for Max Healthcare and a high single-digit impact for Apollo Hospitals. The story points to possible regulatory pressure on hospital earnings, but the final policy details and timing were not stated.